Veracyte Share Price (NASDAQ: VCYT)

$30.27

▲

0.05

(0.17%)

Live

Last updated on August 19, 2025 at 12:37 AM IST

$₹

Check the interactive Veracyte Stock chart to analyse performance

Veracyte stock performance

as on August 19, 2025 at 12:37 AM IST

Today's Low:$30.09
Today's High:$30.59
$30.27
0.59%
Downside
Day's Volatility :1.62%
Upside
1.03%
52 Weeks Low:$22.61
52 Weeks High:$47.32
$30.27
25.31%
Downside
52 Weeks Volatility :52.22%
Upside
36.03%

Veracyte Stock Returns

Period	Veracyte, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	4.21%	2.3%	0.0%
6 Months	-25.24%	-5.8%	0.0%
1 Year	-6.56%	-10.9%	0.0%
3 Years	39.26%	2.8%	-11.6%

Veracyte, Inc. Key Stats

Check Veracyte key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$30.22
Open	$30.0
Today's High	$30.585
Today's Low	$30.09
Market Capitalization	$2.4B
Today's Volume	$1.2M
52 Week High	$47.3162
52 Week Low	$22.61
Revenue TTM	$479.1M
EBITDA	$63.8M
Earnings Per Share (EPS)	$0.34
PE Ratio	88.88
Profit Margin	5.5%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	2.24%

Stock Returns calculator for Veracyte Stock including INR - Dollar returns

The Veracyte stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Veracyte investment value today

Current value as on today

₹97,673

Returns

₹2,327

(-2.33%)

Returns from Veracyte Stock

₹6,401 (-6.4%)

Dollar Returns*

₹4,073 (+4.07%)

Indian investors sentiment towards Veracyte Stock

165%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Search interest for Veracyte Stock from India on INDmoney has increased by 165% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Veracyte, Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
10.51%
BlackRock Inc
9.56%
FMR Inc
9.03%
Artisan Partners Limited Partnership
6.67%
Wellington Management Company LLP
4.90%
ARK Investment Management LLC
4.83%

Analyst Recommendation on Veracyte Stock

Rating

Trend

Buy

73%Buy

20%Hold

6%Sell

Based on 15 Wall street analysts offering stock ratings for Veracyte(by analysts ranked 0 to 5 stars)

Veracyte Share Price Target

What analysts predicted

Upside of 31.32%

Target:

$39.75

Current:

$30.27

Veracyte share price target is $39.75, a slight Upside of 31.32% compared to current price of $30.27 as per analysts' prediction.

Veracyte Stock Insights

Price Movement
In the last 1 month, VCYT stock has moved up by 28.5%
Increasing Revenue
Revenue is up for the last 2 quarters, 114.47M → 130.16M (in $), with an average increase of 12.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 7.04M → -980.0K (in $), with an average decrease of 113.9% per quarter
VCYT vs IDXX (1 yr)
In the last 1 year, Idexx Laboratories, Inc. has given 32.2% return, outperforming this stock by 40.2%
VCYT vs IDXX (3 yr)
In the last 3 years, Idexx Laboratories, Inc. has given 73.7% return, outperforming this stock by 41.3%
Price to Sales
ForVCYT every $1 of sales, investors are willing to pay $4.9, whereas for Idexx Laboratories, Inc., the investors are paying $13.1 for every $1 of sales.

Veracyte, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$120.4M	↑ 30.82%
Net Income	$-16.5M	↓ 28.34%
Net Profit Margin	-13.69%	↑ 11.31%

	FY20	Y/Y Change
Revenue	$117.5M	↓ 2.4%
Net Income	$-35.8M	↑ 117.51%
Net Profit Margin	-30.51%	↓ 16.82%

	FY21	Y/Y Change
Revenue	$219.5M	↑ 86.85%
Net Income	$-75.6M	↑ 110.79%
Net Profit Margin	-34.42%	↓ 3.91%

	FY22	Y/Y Change
Revenue	$296.5M	↑ 35.09%
Net Income	$-36.6M	↓ 51.62%
Net Profit Margin	-12.33%	↑ 22.09%

	FY23	Y/Y Change
Revenue	$361.1M	↑ 21.76%
Net Income	$-74.4M	↑ 103.51%
Net Profit Margin	-20.61%	↓ 8.28%

	FY24	Y/Y Change
Revenue	$445.8M	↑ 23.46%
Net Income	$24.1M	↓ 132.44%
Net Profit Margin	5.41%	↑ 26.02%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$96.8M	↓ 1.38%
Net Income	$-1.9M	↓ 93.41%
Net Profit Margin	-1.92%	↑ 26.89%

	Q2 FY24	Q/Q Change
Revenue	$114.4M	↑ 18.16%
Net Income	$5.7M	↓ 407.62%
Net Profit Margin	5.01%	↑ 6.93%

	Q3 FY24	Q/Q Change
Revenue	$115.9M	↑ 1.25%
Net Income	$15.2M	↑ 164.3%
Net Profit Margin	13.08%	↑ 8.07%

	Q4 FY24	Q/Q Change
Revenue	$118.6M	↑ 2.39%
Net Income	$5.1M	↓ 66.26%
Net Profit Margin	4.31%	↓ 8.77%

	Q1 FY25	Q/Q Change
Revenue	$114.5M	↓ 3.51%
Net Income	$7.0M	↑ 37.83%
Net Profit Margin	6.16%	↑ 1.85%

	Q2 FY25	Q/Q Change
Revenue	$130.2M	↑ 13.71%
Net Income	$-980.0K	↓ 113.91%
Net Profit Margin	-0.75%	↓ 6.91%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$83.8M	↑ 42.28%

	FY20	Y/Y Change
Profit	$76.0M	↓ 9.32%

	FY21	Y/Y Change
Profit	$145.1M	↑ 90.87%

	FY22	Y/Y Change
Profit	$195.0M	↑ 34.35%

	FY23	Y/Y Change
Profit	$248.1M	↑ 27.29%

	FY24	Y/Y Change
Profit	$289.5M	↑ 16.68%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$60.5M	↓ 4.16%

	Q2 FY24	Q/Q Change
Profit	$75.8M	↑ 25.21%

	Q3 FY24	Q/Q Change
Profit	$79.0M	↑ 4.26%

	Q4 FY24	Q/Q Change
Profit	$74.2M	↓ 6.05%

	Q1 FY25	Q/Q Change
Profit	$79.5M	↑ 7.12%

	Q2 FY25	Q/Q Change
Profit	$89.8M	↑ 12.91%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-3.2M	↓ 76.1%
Investing Cash Flow	$-42.7M	↑ 2180.31%
Financing Cash Flow	$127.3M	↑ 113.93%

	FY20	Y/Y Change
Operating Cash Flow	$-9.7M	↑ 200.46%
Investing Cash Flow	$-3.8M	↓ 91.02%
Financing Cash Flow	$203.6M	↑ 59.95%

	FY21	Y/Y Change
Operating Cash Flow	$-31.6M	↑ 225.62%
Investing Cash Flow	$-739.2M	↑ 19165.21%
Financing Cash Flow	$596.3M	↑ 192.9%

	FY22	Y/Y Change
Operating Cash Flow	$7.5M	↓ 123.83%
Investing Cash Flow	$-29.4M	↓ 96.02%
Financing Cash Flow	$3.5M	↓ 99.41%

	FY23	Y/Y Change
Operating Cash Flow	$44.2M	↑ 486.89%
Investing Cash Flow	$15.1M	↓ 151.42%
Financing Cash Flow	$2.8M	↓ 18.8%

	FY24	Y/Y Change
Operating Cash Flow	$75.1M	↑ 69.82%
Investing Cash Flow	$-56.3M	↓ 472.39%
Financing Cash Flow	$4.9M	↑ 72.86%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-9.0M	↓ 157.65%
Investing Cash Flow	$2.9M	↓ 215.26%
Financing Cash Flow	$-864.0K	↓ 233.95%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$29.6M	↓ 429.86%
Investing Cash Flow	$-2.8M	↓ 196.25%
Financing Cash Flow	$-11.0K	↓ 98.73%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$30.0M	↑ 1.31%
Investing Cash Flow	$-2.2M	↓ 19.06%
Financing Cash Flow	$10.3M	↓ 93636.36%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$24.5M	↓ 18.15%
Investing Cash Flow	$-54.1M	↑ 2314.85%
Financing Cash Flow	$-4.5M	↓ 143.83%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$5.4M	↓ 78.14%
Investing Cash Flow	$-51.8M	↓ 4.29%
Financing Cash Flow	$-6.5M	↑ 43.77%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$5.4M	↑ 0.0%
Investing Cash Flow	$-51.8M	↑ 0.0%
Financing Cash Flow	$-6.5M	↑ 0.0%

Veracyte Technicals Summary

Sell

Neutral

Buy

Veracyte is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Veracyte, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Veracyte, Inc.	31.22%	-25.24%	-6.56%	39.26%	-12.66%
Agilent Technologies Inc.	6.39%	-11.83%	-15.17%	-13.38%	21.68%
Idexx Laboratories, Inc.	24.95%	44.93%	30.96%	74.14%	70.6%
Thermo Fisher Scientific, Inc.	20.76%	-6.52%	-19.52%	-16.91%	16.26%
Danaher Corp.	12.16%	3.13%	-22.24%	-27.87%	2.43%
Iqvia Holdings Inc.	20.21%	-1.07%	-21.4%	-20.05%	19.31%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Veracyte, Inc.	88.88	88.88	0.0	1.41	0.02	0.02	NA	15.54
Agilent Technologies Inc.	29.36	29.36	1.75	5.58	0.19	0.08	0.01	21.61
Idexx Laboratories, Inc.	54.06	54.06	4.87	12.6	0.65	0.23	NA	18.2
Thermo Fisher Scientific, Inc.	28.25	28.25	1.99	22.49	0.13	0.05	0.0	133.77
Danaher Corp.	44.88	44.88	2.11	7.77	0.07	0.04	0.01	73.1
Iqvia Holdings Inc.	27.69	27.69	1.1	11.87	0.2	0.05	NA	33.99

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Veracyte, Inc.	Buy	$2.4B	-12.66%	88.88	5.5%
Agilent Technologies Inc.	Buy	$33.9B	21.68%	29.36	17.59%
Idexx Laboratories, Inc.	Buy	$52.1B	70.6%	54.06	24.41%
Thermo Fisher Scientific, Inc.	Buy	$184.7B	16.26%	28.25	15.24%
Danaher Corp.	Buy	$151.0B	2.43%	44.88	14.21%
Iqvia Holdings Inc.	Buy	$32.5B	19.31%	27.69	7.88%

About Veracyte, Inc.

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Organization	Veracyte
Employees	824
CEO	Mr. Marc A. Stapley
Industry	Health Technology

Key Management of Veracyte, Inc.

Name	Title
Mr. Marc A. Stapley	CEO & Director
Ms. Rebecca Chambers	Executive VP & CFO
Dr. Phillip G. Febbo M.D.	Chief Scientific & Medical Officer
Ms. Annie McGuire	Executive VP, General Counsel & Chief People Officer
Dr. John Leite Ph.D.	Global Chief Commercial Officer
Dr. Keith Gligorich Ph.D.	Senior Vice President of Global Operations
Mr. Jonathan Wygant	VP & Chief Accounting Officer
Mr. Steven French	Senior VP & Chief Information Officer
Ms. Karen Possemato	Senior Vice President of Corporate Marketing, Communications & Commercial Operations
Ms. Corinne Danan	Senior Vice President

Important FAQs about investing in VCYT Stock from India :

What is Veracyte share price today?

Veracyte share price today is $30.27 as on August 19, 2025 at 12:37 AM IST. Veracyte share today touched a day high of $30.59 and a low of $30.09.

What is the 52 week high and 52 week low for Veracyte share?

Veracyte share touched a 52 week high of $47.32 and a 52 week low of $22.61. Veracyte stock price today, August 19, 2025 at 12:37 AM IST is trending at $30.27, lower by 36.03% versus the 52 week high.

How to invest in Veracyte Stock (VCYT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Veracyte on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Veracyte Shares that will get you 0.0496 shares as per Veracyte share price of $30.27 per share as on August 19, 2025 at 12:37 AM IST.

What is the minimum amount required to buy Veracyte Stock (VCYT) from India?

Indian investors can start investing in Veracyte (VCYT) shares with as little as ₹87.3775 or $1 (as of August 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹873.77 in Veracyte stock (as per the Rupee-Dollar exchange rate as on August 18, 2025). Based on Veracyte share’s latest price of $30.27 as on August 19, 2025 at 12:37 AM IST, you will get 0.3304 shares of Veracyte. Learn more about fractional shares .

What are the returns that Veracyte has given to Indian investors in the last 5 years?

Veracyte stock has given -12.66% share price returns and 16.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?